Comparative Pharmacology
Head-to-head clinical analysis: ANTEPAR versus VERMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTEPAR versus VERMIDOL.
ANTEPAR vs VERMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
VERMIDOL is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis and attenuating pain, inflammation, and fever.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
200 mg orally twice daily for 3 days; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h) and elderly.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Renal: ~60-70% as unchanged drug; biliary/fecal: ~20-30%; minor metabolism via hepatic CYP3A4.
Category C
Category C
Anthelmintic
Anthelmintic